SHINGRIX tolerability and safety profile
The tolerability and safety of SHINGRIX was evaluated by pooling data from two pivotal Phase III placebo-controlled clinical studies, ZOE-50 and ZOE-70, involving subjects aged ≥50 who received at least one dose of SHINGRIX (n=14,645) or placebo (n=14,660) administered on a 0- and 2-month schedule. 1, 2
- Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang S-J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015 May;372(22):2087-96.
- Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang S-J, Diez-Domingo J, et al. Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016 Sep;375(11):1019-32.